Related Papers
Development of an experimental method using Cs-131 to evaluate radiobiological effects of internalized Auger-electron emitters
2016 •
Pil Fredericia
Preparation and examination of 177Lu- and 90Y-labeled immunoconjugates of Trastuzumab
2019 •
Drina Janković
Trastuzumab is a monoclonal antibody for treatment of HER2 positive breast cancer. Labelled antibody with lutetium-177 and yttrium-90 has been investigated as potential radiopharmaceutical agent for use in radioimmunotherapy. In this study, the labeling was done via DOTA, DTPA and 1B4M-DTPA as a chelator in molar ratios of 1:20. A several chemical techniques have been used to characterize the stability and retained immunoreactivity of the antibody in the formulated immunoconjugates. A protein integrity and purity were proved by applying of reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Vibrational spectroscopy (Infra-red (IR) and Raman spectroscopy) provide molecular structure information and are convenient for verification of changes in the secondary structure. The number of chelating groups per one trastuzumab molecule was calculated by MALDI-TOF-MS. After conjugation, the freeze-drying process was performed in order to obtain stable immunoconjugate...
EJNMMI Radiopharmacy and Chemistry
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
2022 •
Renata Mikolajczak
Bioconjugate chemistry
{"__content__"=>" \nF-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals.", "sup"=>{"__content__"=>"18"}}
2018 •
Krishan Kumar
The clinical applications of positron emission tomography (PET) imaging pharmaceuticals have increased tremendously over the past several years since the approval offluorine-fluorodeoxyglucose (F-FDG) by the Food and Drug Administration (FDA). NumerousF-labeled target-specific potential imaging pharmaceuticals, based on small and large molecules, have been evaluated in preclinical and clinical settings.F-labeling of organic moieties involves the introduction of the radioisotope by C-F bond formation via a nucleophilic or an electrophilic substitution reaction. However, biomolecules, such as peptides, proteins, and oligonucleotides, cannot be radiolabeled via a C-F bond formation as these reactions involve harsh conditions, including organic solvents, high temperature, and nonphysiological conditions. Several approaches, includingF-labeled prosthetic groups, silicon, boron, and aluminum fluoride acceptor chemistry, and click chemistry have been developed, in the past, forF labeling o...
International Journal of Molecular Sciences
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Vasile Chis
Positron emission tomography (PET) uses radioactive tracers and enables the functional imaging of several metabolic processes, blood flow measurements, regional chemical composition, and/or chemical absorption. Depending on the targeted processes within the living organism, different tracers are used for various medical conditions, such as cancer, particular brain pathologies, cardiac events, and bone lesions, where the most commonly used tracers are radiolabeled with 18F (e.g., [18F]-FDG and NA [18F]). Oxygen-15 isotope is mostly involved in blood flow measurements, whereas a wide array of 11C-based compounds have also been developed for neuronal disorders according to the affected neuroreceptors, prostate cancer, and lung carcinomas. In contrast, the single-photon emission computed tomography (SPECT) technique uses gamma-emitting radioisotopes and can be used to diagnose strokes, seizures, bone illnesses, and infections by gauging the blood flow and radio distribution within tissu...
Theranostics
Prospective of ⁶⁸Ga-radiopharmaceutical development
2013 •
Irina Velikyan
Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the ⁶⁸Ga-radiopharmaceuticals must be put in the context of several aspects such as role of PET in nuclear medicine, unmet medical needs, identification of new biomarkers, targets and corresponding ligands, production and availability of ⁶⁸Ga, automation of the radiopharmaceutical production, progress of positron emission tomography technologies and image analysis methodologies for improved quantitation accuracy, PET radiopharmaceutical regulations as well as advances in radiopharmaceutical chemistry. The review presents the prospects of the ⁶⁸Ga-based radiopharmaceutical development on the basis of the current stat...
European Journal of Nuclear Medicine and Molecular Imaging
Comparative evaluation of anti-EFGR affibody molecules labelled with gallium-68 and zirconium-89 using desferrioxamine B as a chelator
2018 •
maryam oroujeni
EJNMMI Radiopharmacy and Chemistry
Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
2021 •
Piotr Garnuszek
In the frame of “precision medicine”, the scandium radionuclides have recently received considerable interest, providing personalised adjustment of radiation characteristics to optimize the efficiency of medical care or therapeutic benefit for particular groups of patients. Radionuclides of scandium, namely scandium-43 and scandium-44 (43/44Sc) as positron emitters and scandium-47 (47Sc), beta-radiation emitter, seem to fit ideally into the concept of theranostic pair. This paper aims to review the work on scandium isotopes production, coordination chemistry, radiolabeling, preclinical studies and the very first clinical studies. Finally, standardized procedures for scandium-based radiopharmaceuticals have been proposed as a basis to pave the way for elaboration of the Ph.Eur. monographs for perspective scandium radionuclides.
Theranostics
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
2021 •
Janke Kleynhans
EJNMMI Radiopharmacy and Chemistry
Synthesis of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
Javier Giglio
